Introduction

In incretin research, one major trend has been the shift from single-receptor GLP-1 models toward dual- and triple-receptor agonist models. Researchers comparing metabolic signaling pathways often group these compounds into three related categories: GLP-1 S, GLP-2 TZ, and GLP-3 R.

These product names correspond to common research shorthand often described as Sema, Tirz, and Reta, respectively:

• GLP-1 S / Sema — single-pathway GLP-1 receptor research
• GLP-2 TZ / Tirz — dual GLP-1 and GIP receptor research
• GLP-3 R / Reta — triple GLP-1, GIP, and glucagon receptor research

This guide compares GLP-2 TZ (Tirz), GLP-3 R (Reta), and GLP-1 S (Sema) across receptor profile, research applications, testing considerations, and product-selection factors.

Published preclinical literature includes both cell-based and animal-model research, while clinical literature describes semaglutide as a GLP-1 receptor agonist, tirzepatide as a dual GIP/GLP-1 receptor agonist, and retatrutide as a GIP, GLP-1, and glucagon receptor agonist.¹ ² ³ Honest Peptide products are sold strictly for laboratory research use only and are not for human or animal use.

Quick Comparison: GLP-1 S vs GLP-2 TZ vs GLP-3 R

Research Name	Common Shorthand	Receptor Model	Research Category	Key Pathway
GLP-1 S	Sema	GLP-1 receptor	Single agonist	Baseline GLP-1 pathway model
GLP-2 TZ	Tirz	GLP-1 + GIP receptors	Dual agonist	Adds GIP signaling to GLP-1 research
GLP-3 R	Reta	GLP-1 + GIP + glucagon receptors	Triple agonist	Adds glucagon signaling to GLP-1/GIP research

In published research, GLP-1 receptor activation is associated with glucose-dependent insulin secretion, glucagon regulation, gastric emptying, and appetite-related signaling.¹ GLP-2 TZ related research introduced a dual GIP/GLP-1 agonist model, while GLP-3 R related research extended this approach to a triple GIP/GLP-1/glucagon receptor model.² ³

---

GLP-1 S / Sema: Single-Receptor GLP-1 Research

GLP-1 S, commonly referred to as Sema, represents the single-pathway reference point in this comparison. GLP-1 receptor agonism is widely studied in metabolic research because GLP-1 signaling is associated with glucose-dependent insulin secretion, glucagon regulation, gastric emptying, and appetite-related pathways.¹

At the cellular level, GLP-1 receptor activation is linked to adenylate cyclase activity and increased intracellular cyclic AMP signaling in pancreatic beta-cell models.¹ This makes GLP-1 S useful as a baseline comparator when researchers evaluate dual-agonist and triple-agonist models.

Research focus areas include:

• GLP-1 receptor activation
• cAMP-linked signaling models
• glucose and insulin signaling research
• appetite and satiety pathway studies
• comparison with dual and triple agonist models

For product specifications, purity information, and COA details, see GLP-1 S (Sema)

GLP-2 TZ / Tirz: Dual GLP-1 and GIP Research

GLP-2 TZ, commonly referred to as Tirz, is associated with dual incretin pathway research involving both GLP-1 and GIP receptor activity. In published literature, tirzepatide is described as a fatty-acid-modified peptide with dual GIP and GLP-1 receptor agonist activity.²

This dual-receptor profile makes GLP-2 TZ especially relevant for researchers studying how GLP-1 and GIP signaling may interact. Compared with GLP-1 S / Sema, GLP-2 TZ introduces GIP receptor activity as a second incretin pathway.

Research focus areas include:

• dual GLP-1/GIP receptor signaling
• incretin pathway interaction
• GIP receptor activity in metabolic models
• comparison with GLP-1-only research compounds
• comparison with triple-agonist GLP-3 R / Reta models

For lot-specific testing, guaranteed 99%+ purity data, and product specifications, see GLP-2 TZ (Tirz)

GLP-3 R / Reta: Triple GLP-1, GIP, and Glucagon Research

GLP-3 R, commonly referred to as Reta, is associated with triple-receptor incretin research. In published clinical literature, retatrutide, also known as LY3437943, is described as an agonist of the GIP, GLP-1, and glucagon receptors.³

This triple-receptor profile makes GLP-3 R a common point of comparison against both GLP-1 S / Sema and GLP-2 TZ / Tirz. While GLP-1 S focuses on GLP-1 receptor activity and GLP-2 TZ adds GIP receptor activity, GLP-3 R introduces glucagon receptor activity into the research model.

Preclinical research on GLP-1/GIP/glucagon triple agonists has investigated body-weight regulation and energy-expenditure-related mechanisms in diet-induced obesity models.⁴ These findings provide scientific context for why GLP-3 R / Reta is often discussed as a next-generation incretin research category.

Research focus areas include:

• GLP-1/GIP/glucagon receptor signaling
• triple-agonist pathway research
• energy-balance-related metabolic models
• comparison with dual-agonist models
• next-generation incretin signaling studies

For product specifications, third-party testing, guaranteed 99%+ purity data, and COA details, see GLP-3 R (Reta)

Single vs Dual vs Triple Agonist Research Models

The main difference between GLP-1 S, GLP-2 TZ, and GLP-3 R is the number and type of receptor pathways involved.

GLP-1 S / Sema: Single-Pathway Model

GLP-1 S centers on the GLP-1 receptor pathway. This makes it useful as a baseline model for GLP-1 receptor-focused research.

GLP-2 TZ / Tirz: Dual-Pathway Model

GLP-2 TZ adds GIP receptor activity alongside GLP-1 receptor activity. This dual-pathway model is useful when researchers want to study how GLP-1 and GIP signaling may interact in metabolic research systems.

GLP-3 R / Reta: Triple-Pathway Model

GLP-3 R adds glucagon receptor activity to the GLP-1/GIP framework. This makes it relevant for research models focused on broader incretin and metabolic pathway interaction.

GLP-2 TZ vs GLP-3 R: Why Researchers Compare Tirz and Reta

One of the most important comparisons in this category is GLP-2 TZ vs GLP-3 R, or Tirz vs Reta.

The reason is straightforward: both are multi-receptor incretin research categories, but they differ in pathway complexity.

Comparison Point	GLP-2 TZ (Tirz)	RGLP-3 R / Reta
Receptor Model	GLP-1 + GIP	GLP-1 + GIP + glucagon
Research Category	Dual agonist	Triple agonist
Main Distinction	Adds GIP to GLP-1 signaling	Adds glucagon to GLP-1/GIP signaling
Research Use Case	Dual incretin pathway studies	Multi-receptor incretin pathway studies
Comparison Value	Useful midpoint between GLP-1-only and triple models	Useful for studying next-generation incretin signaling

This is why GLP-2 TZ and GLP-3 R are often discussed together in research settings. GLP-2 TZ / Tirz represents a dual-pathway model, while GLP-3 R / Reta represents a triple-pathway model. Researchers evaluating dual versus triple incretin signaling may compare GLP-2 TZ/ Tirz (research peptide) with GLP-3 R/Reta (research peptide) to study differences in receptor-targeting strategy, model design, and pathway complexity.

GLP-1 S vs GLP-3 R: Sema vs Reta

The GLP-1 S vs GLP-3 R comparison is a single-pathway versus triple-pathway comparison.

GLP-1 S / Sema is centered on GLP-1 receptor signaling. GLP-3 R / Reta is associated with GLP-1, GIP, and glucagon receptor signaling.³ This makes GLP-3 R relevant for research models studying broader incretin pathway interaction.

In published research, retatrutide has been evaluated as a triple-hormone-receptor agonist.³ These clinical data are not claims regarding research-use-only products, but they provide context for why GLP-3 R / Reta receives significant research attention.

Receptor and Signaling Considerations

Pathway	Research Relevance
GLP-1 receptor	GcAMP-linked signaling, insulin secretion models, glucagon regulation, gastric-emptying research, appetite-related pathways
GIP receptor	incretin pathway interaction, adipose-related metabolic signaling, comparison with GLP-1-only models
Glucagon receptor	hepatic signaling, energy-balance-related pathway research, triple-agonist model design

GLP-1 S, GLP-2 TZ, and GLP-3 R therefore represent a progression from single-receptor to multi-receptor research models. The goal of comparing them is not to identify a universally “best” compound, but to match receptor profile to the study design.

Testing, Purity, and COA Considerations

When comparing GLP-1 S, GLP-2 TZ, and GLP-3 R research peptides, researchers should consider not only the receptor profile, but also the quality documentation behind each product.

Key quality factors include:

• HPLC purity testing — verifies peptide purity
• Mass spectrometry confirmation — supports identity verification
• Peptide content / fill verification — helps confirm actual material present
• Endotoxin testing — important for sensitive research applications
• Heavy metals testing — helps identify inorganic contaminants
• Lot-specific COAs — allow researchers to match testing data to the received batch

Honest Peptide provides third-party testing and lot-specific COA documentation for GLP research peptides where available. GLP-2 TZ, GLP-3 R, and GLP-1 S are supplied with guaranteed 99%+ purity.

Related product pages:

• GLP-2 TZ / Tirz 10mg research peptide
• GLP-3 R / Reta 10mg research peptide
• GLP-1 S / Sema research peptide

References

1.Knerr PJ, Mowery SA, Finan B, et al. Next Generation GLP-1/GIP/Glucagon Triple Agonists Normalize Body Weight in Obese Mice. Molecular Metabolism. 2022;63:101533. The PubMed record describes optimized triagonists in diet-induced obesity mouse models and energy-expenditure-related findings.

2. Holst JJ. The Physiology of Glucagon-Like Peptide 1. Physiological Reviews. 2007;87(4):1409-1439. GLP-1 is described as a peptide hormone with effects on insulin secretion, glucagon secretion, gastrointestinal secretion, motility, and appetite-related pathways.

3. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus. Molecular Metabolism. 2018;18:3-14. LY3298176 is described as a fatty-acid-modified peptide with dual GIP and GLP-1 receptor agonist activity.

4.Jastreboff AM, Kaplan LM, Frias JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. 2023. Retatrutide, also known as LY3437943, is described as a single peptide with agonism toward GIP, GLP-1, and glucagon receptors.